A. Karim Kader, MD, PhD, FRCSC, presented “The Role of Genetic Testing in Prostate Cancer” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Kader, A. Karim. “The Role of Genetic Testing in Prostate Cancer” January 23rd, 2020. Accessed Nov 2024. https://grandroundsinurology.com/the-role-of-genetic-testing-in-prostate-cancer/
The Role of Genetic Testing in Prostate Cancer – Summary:
A. Karim Kader, MD, PhD, FRCSC, Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, argues that genomic risk stratification plays an important role in our understanding of prostate cancer. He highlights the differences between germline and somatic genomic classifiers and the impact they can have on prostate cancer risk and outcome. Dr. Kader discusses the advantages and disadvantages of a wide range of genetic tests. Additionally, he discusses the differences between high penetrance and low penetrance genetic change and the implications they can have on screening, detection, and treatment decisions.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Dr. Kader delivered this educational activity during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in screening, detecting, treating and preventing prostate cancer. He has successfully a genetic test to predict lifetime risk of developing prostate cancer. As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include artificial intelligence in healthcare and the use of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston and a Residency in Urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.